Investor Announcements

Asieris Included in the SSE STAR Biology and Medicine Index

Asieris Pharmaceuticals Lands on STAR Market

Asieris Announces the Completion of their Series D Round of Financing

Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization

Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs

Asieris Announced Follow-on Investment to its B Round Funding

Asieris Announced Closing of Series B Funding Round in Excess of 100 Million RMB

Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

Highlights of Asieris Pharmaceuticals 2022 Annual Report